JointHealth™ express September 26, 2013
The JointHealth™ report card is Canada’s only independent, annual patient organization evaluation of public reimbursement access to arthritis medications. Arthritis Consumer Experts (ACE) publishes the report card in print and online. For up-to-date biologic medication listings, please visit our interactive online report card here.
As part of Arthritis Awareness Month in Canada, ACE would like to acknowledge the efforts of all the provinces and territories who had biologic medications approved over the past 12 months.
Arthritis Consumer Experts has provided a table of summary of all the approved biologic medications in Canada, organized by provinces and biologic medications. Since September 2012, Newfoundland and Labrador and Yukon did not have any changes in their provincial drug formulary.
People with arthritis, with the help of the doctors who treat them, deserve to be able to choose medication most appropriate for their specific risk factors. The Arthritis Alliance of Canada reports that the early diagnosis and treatment of inflammatory arthritis with cost effective disease modifying anti-rheumatic drugs (DMARDs) is essential, and that for those who do not respond to traditional DMARDs, access to biologic therapies results in significant savings in health care costs and reductions in work disability.
The continuous improvement of arthritis care is an urgent national priority. We call on the public to review the recent performances of provincial and territory governments and contact your local MP, MLA or MPP and ask for their commitment to ensure biologics for inflammatory arthritis are listed in an equitable fashion as the science proves they should be.
For tips on how to communicate with elected officials or key decision-makers, please visit our “What you can do” page within the “Taking Action” section of the JointHealth™ website. Click here to find out how your province or territory is doing.
The JointHealth™ report card is Canada’s only independent, annual patient organization evaluation of public reimbursement access to arthritis medications. Arthritis Consumer Experts (ACE) publishes the report card in print and online. For up-to-date biologic medication listings, please visit our interactive online report card here.
As part of Arthritis Awareness Month in Canada, ACE would like to acknowledge the efforts of all the provinces and territories who had biologic medications approved over the past 12 months.
Arthritis Consumer Experts has provided a table of summary of all the approved biologic medications in Canada, organized by provinces and biologic medications. Since September 2012, Newfoundland and Labrador and Yukon did not have any changes in their provincial drug formulary.
People with arthritis, with the help of the doctors who treat them, deserve to be able to choose medication most appropriate for their specific risk factors. The Arthritis Alliance of Canada reports that the early diagnosis and treatment of inflammatory arthritis with cost effective disease modifying anti-rheumatic drugs (DMARDs) is essential, and that for those who do not respond to traditional DMARDs, access to biologic therapies results in significant savings in health care costs and reductions in work disability.
The continuous improvement of arthritis care is an urgent national priority. We call on the public to review the recent performances of provincial and territory governments and contact your local MP, MLA or MPP and ask for their commitment to ensure biologics for inflammatory arthritis are listed in an equitable fashion as the science proves they should be.
For tips on how to communicate with elected officials or key decision-makers, please visit our “What you can do” page within the “Taking Action” section of the JointHealth™ website. Click here to find out how your province or territory is doing.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.